The 3 month extension of the 3rd Eye loan deadline to Aug 4th plus the fact that 3rd Eye did not seem to take action when the covenant to deliver top-line results by the Jan 31 suggests to me they are not really interested in taking control of the RVX assets. IMHO it releives another stress point.

It also suggests RVX is having a challenge in raising capital to keep the ship afloat until the BoM results are ready but that is always the situation and I’m sure Don will come through, at least based on 20 years of success in raising funds.

At Aug 4th RVX will be 1 month into H2 and will have had 3 months to close out the trial and possibly receive data.

A successful BoM might be the catalyst that moves the SP up enough for a NASDAQ listing. The MD & A makes it clear that they will need to keep raising capital until well into the future for the other trials and to get to the point where apabetalone is on the market and generating royalties.

I'm excited to start to see the licensing deals happen after BoM success and also who might in big.

GLTA

Toinv